GMP Warnings Split Between Brand, Generic Firms; Congress Watches FDA

The number of prescription drug manufacturing warning letters from FDA remained roughly split between brands and generics during the last year, but brands dominated the citations in early 2008, in contrast to generics' dominance since mid-year, when the House Energy and Commerce Committee launched an investigation into the agency's handling of products produced by Ranbaxy